At Oncopeptides, we are dedicated to turning research into therapies that change lives. This is how we do it.
Multiple myeloma is an incurable blood cancer. Symptoms like bone pain, fatigue, and infections severely reduce quality of life. Despite advances in treatment, most patients eventually relapse and become resistant to all available therapies, creating a critical need for innovative options.
Melflufen is the first treatment of its kind, developed to deliver cancer-killing agents directly inside multiple myeloma cells. It uses enzymes in these cells to activate and release its active substance, damaging cancer DNA and helping to stop disease progression.
